Alzheimer ’ s Disease Neuroimaging Initiative 3 (ADNI 3) Michael W. Weiner
ADNI3 WILL (Probably) BE FUNDED
The “ Problem ” will be retention of ADNI 2 subjects And recruitment of new subjects!
ACCOMPLISHMENTS OF ADNI • Validation of “ amyloid phenotyping ” • Over 1022 publications from ADNI • Data widely used for design of AD clinical trials – Growing trials, problem for ADNI recruitment
ONGOING TRIALS COMPETING FOR SUBJECTS • List provided by PPSB members • This is not a thorough review of clinicaltrials.gov • At least 14 major trials: CN, MCI, AD
Prodromal TRIALS in 2016 (from Mike Egan) Sponsor Mode of Phase Status Study Start- Action/Drug Completion Merck BACE Inhibitor Phase III Recruiting Nov 2013- July 2019 MK-8931 (N=1,500) Sep 2014 – Aug 2019 Eli Lilly BACE Inhibitor Phase II/III Recruiting AstraZeneca AZD3293 (N = 2,200) Eli Lilly BACE Inhibitor Phase III planned AstraZeneca AZD3293 (N = >1,500) Mid 2016 – 2020 Eli Lilly solanezumab Phase III planned LY2599666 (projected) (N = >1,000) (projected) Aug 2015 – Feb 2020 Biogen Aducanumab Phase III Recruiting (BIIB037) (N = 1350) Sep 2015 – Feb 2020 Biogen Aducanumab Phase III Recruiting (BIIB037) (N = 1350 Nov 2014 – Jan 2018 Biogen BACE Inhibitor Phase II Recruiting Eisai Inc. E2609 (N = 700) AZTherapies ALZT-OP1 Phase III Recruiting Sept 2015-March 2018 (N = 600)
MORE TRIALS • Eisai: BAN2401 – antibody prodromal and mild AD • Eisai E-2609 - BACE inhibitor Prodromal AD • Roche: Crenezumab Prodromal/Mild AD • Lilly A4, and Janssen A5 (Early) cognitively normal • TRACK-PAD: CN and Prodromal • COMPETITION IS GOING MAKE ADNI ENROLLMENT DIFFICULT
ADNI 3 STUDY DESIGN • Roll over of ADNI 2 subjects • Enrollment of new ADNI 3 subjects • Brain Health Registry helps recruitment • Annual visits • All subjects have baseline visit • Addition of “ financial capacity ” instrument • Amyloid PET and LP alternate years • Frequent Tau PET and MRIs • On-line cognitive assessments • Continue to collect autopsy material
ADNI3: Schedule of Events Rollover and New Subjects Baseline 12 month 24 month 36 month 48 month CV, MRI, Tau (+/-), CV, MRI, Tau (+/-) OR CN CV, MRI, Tau, AMY, LP Phone Check CV, MRI, Tau, AMY, LP AMY, LP Phone Check CV, MRI, Tau, AMY, LP, CV, MRI, Tau (+/-), MCI CV, MRI CV, MRI, Tau (+/-) CV, MRI, Tau, AMY, LP FDG AMY, LP CV, MRI, Tau, AMY, LP, Phone Check Phone Check AD CV, MRI, Tau CV, MRI, Tau, AMY, LP FDG (Neuropath only) (Neuropath only) Rollovers continue with Florbetapir; New enrollees have Florbetaben Tau scans for CN and MCI depend on amyloid status and randomization: All CN, MCI, and AD have tau PET at beginning and end 80% of amyloid+ CN and MCI have frequent tau scans 80% of amyloid – CN and MCI only have Tau PET at beginning/end Randomization used, to avoid revealing amyloid status
HIGHLIGHTS OF CORES • CLINICAL: ATRI, BHR, Financial cap,Cogstate • MRI: Connectome protocol • PET: Tau, Amyloid (2 tracers), FDG • BIOMARKER: Roche platform • GENETICS: Systems Biology • PATHOLOGY: Continued need for autopsies • BIOSTAT: Clinical trial design • INFORMATICS: User friendly access
THE BIG PROBLEMS • Overall, the problem is recruitment/retention • Importance of continuing ADNI2 rollovers – Past problem of high dropout rate ADNI1/2 – Please encourage subjects to continue in ADNI • Difficulty in enrolling new subjects – High subject burden – Competing clinical trials • We are very welcome of suggestions
EMA 24 November, 2014 Workshop on Alzheimer's disease Novel Regulatory
Caring for a Loved One with Alzheimer's Disease Peggy Higgins Emeritus
Alzheimer s Disease, Infectious type Evidence from Harvard Brain Bank Cases
Erik BUNTINX , MD-Psychiatrist Founding CEO erik.buntinx@aneurotech.com 1
I nsulin Resistance and I nsulin Resistance and Alzheimer s Disease: s
The choice of outcome parameters and need for distinct assessment tools with
Discovering new Alzheimer disease related genes and gene networks through
Arterial Stiffness and Alzheimer Disease, a simple association? Pr. A.
Understanding Alzheimer's Dr. Bill Ketelbey CEO & Managing Director
Blood Flow to the Brain and Dementia Osman Shabir NICAD (Neuroimaging in
Effects of Soft Wheat traits on wheat flour to make batters and breaders
DDW 2019 THE BEST OF THE BEST ABSTRACTS AND PRESENTATIONS ABOUT ERCP FRANKLIN
MANAGEMENT OF NON- COELIAC GLUTEN SENSITIVITY Dr Sue Shepherd B.App.Sci.
Integrative Biorefinery research@IBL Conversion of renewable plant biomass to
Pardon Gomani CALENDAR OF EVENTS Prior to site activation the following events
Thailand 14 active Novacq ponds Australia - Yamba active Novacq ponds THE
Persistence of BAN2401-Mediated Amyloid Reductions Post-Treatment: A
Case Report Ear, Nose & Throat Journal 14 A Rare Nasopharyngeal
Variable Presentation and Pathologic Overlap of Rare Neuromuscular Condition
Progress in detecting prions and diagnosing prion diseases Byron Caughey
To Fold or to Misfold: What is the Problem? (Molecular Origami) Sheena E
Long-term safety and efficacy of AG10 in ATTR-CM: Phase 2 Open Label